ExxonMobil has begun commercial operations of a significant carbon capture and storage venture with CF Industries in Louisiana, marking a key step in its strategy to become a leading player in the emerging CCS network along the U.S. Gulf Coast.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
In a significant industry pivot, Nasdaq-listed Bit Digital announces plans to completely exit Bitcoin mining, citing capital inefficiency and redirecting focus to Ethereum infrastructure and AI. This move follows a broader trend of crypto firms abandoning mining operations post-halving and amidst the AI boom.
Brookfield Business Partners (BBU) reports a strong 2025 defined by strategic capital moves and operational gains across its portfolio. The company is on the cusp of a major corporate reorganization into a single listed entity, aiming to boost liquidity and attract a wider investor base.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
Despite a challenging freight market, ArcBest reports resilient fourth-quarter performance, highlighting strategic cost controls, a turnaround in its asset-light segment, and significant investments in AI and automation to drive future efficiency.
Shares of USA Rare Earth (NASDAQ: USAR) recovered Wednesday following a sharp sell-off, buoyed by an analyst's upgraded price target and reinforced by a recent $3.5 billion capital infusion from public and private sources.
As 2026 unfolds, the AI investment thesis is maturing beyond initial skepticism, creating opportunities in both leading tech giants and overlooked sectors. We analyze five companies, from semiconductor powerhouses to regional e-commerce leaders, positioned for a pivotal year.
After two challenging years, Flagstar Bancorp (NYSE: FBC) reported a return to profitability in the fourth quarter of 2025, posting adjusted net income of $30 million. Executives outlined a strategic shift towards commercial lending and a strengthened balance sheet as key drivers for future performance.
Shares of International Paper (IP) have retreated sharply in recent sessions, underperforming its longer-term track record and prompting a fresh debate among investors over whether the packaging giant is now undervalued or facing deeper headwinds.
In a strategic move to reduce reliance on foreign tech giants, Japan launches a national AI initiative, combining SoftBank's leadership with substantial government backing to develop a domestic foundational model.
As copper prices surge over 40% since August, driven by supply constraints and green energy demand, investors are eyeing major producers BHP, Freeport-McMoRan, and Southern Copper, each offering a distinct path to exposure in the red-hot market.
The U.S. Justice Department has begun releasing over three million pages from the Jeffrey Epstein investigation, including photos and videos. The long-awaited document dump intensifies scrutiny on the financier's powerful associates, including former Presidents Trump and Clinton, amid accusations of a high-level cover-up.
U.S. stock futures turned lower Friday morning following President Trump's announcement nominating former Fed Governor Kevin Warsh to chair the Federal Reserve, replacing Jerome Powell. The move injects fresh uncertainty into monetary policy outlook.
Brookfield Business Partners reported a robust 2025, generating over $2 billion from asset sales, reducing debt, and making strategic acquisitions. The firm is on the cusp of a major corporate restructuring into a single listed entity, aiming to boost liquidity and investor appeal in a shifting global landscape.
Despite a prolonged freight recession, ArcBest reports resilient fourth-quarter performance, driven by strategic cost controls, AI integration, and growth in managed logistics solutions, while outlining a cautious outlook for 2026.
Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.
Since its spin-off from GE Aerospace, GE Vernova's stock has soared over 400%. While its position in gas, wind, and next-gen nuclear power is formidable, sky-high valuations give even growth investors pause.
Air Products and Chemicals reported a 10% rise in adjusted EPS for its fiscal first quarter, driven by strategic pricing and productivity gains. While management affirmed full-year guidance, they highlighted persistent challenges in the helium market and a cautious approach to major clean energy investments.
Allegro MicroSystems (ALGM) has restructured its credit facilities, securing $285 million in new term loans maturing in 2030. The move provides the semiconductor firm with fresh capital for corporate initiatives as it navigates a capital-intensive sector while maintaining a premium market valuation.
